Can autologous thrombin with a rest fraction of ethanol be used safely for activation of concentrated autologous platelets applied on nerves?

Somer, Filip De; Brauwer, Veerle De; Vandekerckhove, Maxence; Ducatelle, Richard; Uyttendaele, Dirk; Nooten, Guido Van

doi:10.1007/s00586-005-0962-y

Cited by 12 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another alternative to avoid the use of bovine thrombin to activate PRP is autogenous thrombin. However, independent of the technique used for its preparation, the final thrombin activity is difficult to predict (De Somer et al 2006). In addition, the traditional technique for preparing autogenous thrombin uses a portion of the PRP in this process, thus reducing the amount of PRP available for clinical use (De Somer et al 2006).…”

Section: Discussionmentioning

confidence: 99%

Effect of platelet‐rich plasma on bone healing of autogenous bone grafts in critical‐size defects

Nagata

Melo

Messora

et al. 2009

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of platelet‐rich plasma on bone healing of autogenous bone grafts in critical‐size defects

Nagata

Melo

Messora

et al. 2009

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

“…The liquid part in this syringe contains AT with a concentration of at least 50 IU/ml. 20 Platelet-Leukocyte Gel Production PLG was produced shortly before application to the bacterial cultures. PRP was mixed with AT in a 10:1 ratio to create PLG.…”

Section: Autologous Thrombin Preparationmentioning

confidence: 99%

Antimicrobial activity of platelet‐leukocyte gel against Staphylococcus aureus

Moojen

Everts

Schure

et al. 2007

Journal Orthopaedic Research

293

216

View full text Add to dashboard Cite

Platelet-leukocyte gel (PLG) contains high concentrations of platelets and leukocytes. As leukocytes play an important role in the innate host-defense, we hypothesized that PLG might have antimicrobial properties. This study investigated the antimicrobial activity of PLG against Staphylococcus aureus and the contribution of myeloperoxidase (MPO), present in leukocytes, in this process. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were obtained from whole blood of six donors. PLG was prepared by mixing PRP with autologous (PLG-AT) or bovine thrombin (PLG-BT). Antimicrobial activity of PLG-AT, PLG-BT, PRP, and PPP was determined in a bacterial kill assay. MPO release was measured by ELISA and activity was measured using a MPO activity assay. Cultures showed a rapid decrease in the number of bacteria for both PLG-AT and PLG-BT, which was maximal between 4 and 8 h, to approximately 1% of the bacteria in controls. The effect of PLG-AT was largest and significantly different compared to PRP ( p ¼ 0.004) and PPP ( p < 0.001), however not compared to PLG-BT ( p ¼ 0.093). PLG-AT, PLG-BT, and PRP showed a comparable, gradually increasing MPO release. MPO activity was comparable for all groups and remained stable. No correlation between MPO release, activity, and bacterial kill could be found. PLG appears to have potent antimicrobial capacity, but the role of MPO in this activity is questionable. PLG might represent a useful strategy against postoperative infections. However, additional research should elucidate its exact antimicrobial activity. ß

show abstract

“…In the United States, the use of bovine thrombin is allowed; in European countries and in Japan, bovine derivatives are still considered to bring unacceptable risks. For this reason, autologous thrombin is frequently used [47,94]. Thrombin cleaves fibrinogen, and polymerized fibrin produces the clot.…”

Section: Can Technical Weakness or Trouble Affect The Clinical Efficamentioning

confidence: 99%

Platelet‐rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point?

Borzini

Mazzucco

2007

ISBT Science Series

View full text Add to dashboard Cite

Background PubMed accessed on January 23 revealed 160 items about ‘platelet gel or releasate’ associated to topical therapy. Yahoo! provided 8580 items; Altavista 8650; Google 25 300. Companies providing blood separators are going to offer devices to prepare platelet‐rich plasma (PRP) for topical therapy. Several devices are filling the marketplace aiming to produce platelet gels for human therapy. Never‐ending lists of clinical conditions supposed to benefit from platelet gel application are published. Clinical benefits include bactericidal activity, pain reduction, tissue repair and regeneration. Are platelet derivatives the magic bullet for topical therapy? Methods Many in vitro studies account for clinical benefit from platelet gel. Several in vivo studies provide clinical evidence about healing of tissue repair induced by platelet derivatives. Nevertheless, systematic reviews reveal inadequate studies providing enough methodological strength to confirm evidence‐based efficacy. At present we must deal the subject with care using mostly inductive criteria. Only reproducible scientific data are to be considered. Every effort should be made for commercial, private and personal popularity‐related scenarios to be rejected from our consideration. Sometimes, this is not so simple to be done. Results There is a list of more than 60 biologically active platelet‐derived factors directly involved in tissue repair mechanisms: chemotaxis, cell proliferation, angiogenesis, extracellular matrix deposition and remodelling. Biological functions are also indirectly mediated by platelet‐derived growth factors; such functions are triggered by chemokines and cytokines produced by bystander cells such as fibroblasts, macrophages, endothelial cells, lymphocytes, under platelet‐derived factor stimulation. All of this is well demonstrated. Clinical studies endorsed with stringent randomized controlled trials are lacking. However, several serious studies have been published reporting clinical efficacy of platelet derivatives in many clinical areas. Considering these papers seriously, we maintain that in most cases, clinical efficacy is by far more than just a suggestion. Discussion Although we consider evidence‐based medicine (EBM) highly meaningful, we emphasize that medicine moved forwards also before EBM was conceived. We do not consider platelet gel and releasate such as a ‘magic bullet’, but we are strongly impressed by the results our group, and other groups have obtained treating a variety of tissue lesions in a variety of clinical conditions. Clinical benefits are a composite result of the lesion state, severity and duration, coexisting pathologies, patient's age and product characteristics. From our point of view, the last is a pivotal variable that has strong influence over the clinical outcome. Platelet‐rich plasma, platelet gel and platelet releasate need stringent definitions. Too many methods are used to prepare these products. Both methods and product need definition, validation, specific quality parameters and clin...

show abstract

Can autologous thrombin with a rest fraction of ethanol be used safely for activation of concentrated autologous platelets applied on nerves?

Cited by 12 publications

References 10 publications

Effect of platelet‐rich plasma on bone healing of autogenous bone grafts in critical‐size defects

Effect of platelet‐rich plasma on bone healing of autogenous bone grafts in critical‐size defects

Antimicrobial activity of platelet‐leukocyte gel against Staphylococcus aureus

Platelet‐rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biologic view point?

Contact Info

Product

Resources

About